Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling

Kidney International

Volumn 65, Issue 1, 2004, Pages 63-74

  Fukasawa, Hirotaka ^a   Yamamoto, Tatsuo ^b   Suzuki, Hiroyuki ^b   Togawa, Akashi ^b   Ohashi, Naro ^b   Fujigaki, Yoshihide ^b   Uchida, Chiharu ^b   Aoki, Michiko ^b   Hosono, Mareto ^b   Kitagawa, Masatoshi ^b   Hishida, Akira ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Anti TGF antibody ( T); Chronic progressive glomerulonephritis; Renal fibrosis; Smad; Smad binding element (SBE); Transforming growth factor (TGF )

Indexed keywords

COLLAGEN TYPE 1; HYDROXYPROLINE; IMMUNOGLOBULIN G; MESSENGER RNA; NITROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY FIBROSIS; MALE; NEPHRITIS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0347992790     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00393.x     Document Type: Article

References (33)

1. BORDER WA, RUOSLAHTI E: Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 90:1-7, 1992
2. EDDY AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
3. DERYNCK R, ZHANG Y, FENG XH: Smads: Transcriptional activators of TGF-beta responses. Cell 95:737-740, 1998
4. BORDER WA, OKUDA S, LANGUINO LR, et al: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371-374, 1990
5. SHARMA K, JIN Y, GUO J. et al: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530, 1996
6. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
7. MIYAJIMA A, CHEN J, LAWRENCE C, et al: Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 58:2301-2313, 2000
8. ISLAM M, BURKE JF, JR, MCGOWAN TA, et al: Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 59:498-506, 2001
9. LING H, LI X, JHA S, et al: Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: Morphologic improvement associated with functional preservation. J Am Soc Nephrol 14:377-388, 2003
10. AKAGI Y, ISAKA Y, ARAI M, et al: Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50:148-155, 1996
11. BORDER WA, NOBLE NA, YAMAMOTO T, et al: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
12. SHARMA K, ZIYADEH FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266:F829-842, 1994
13. YAMAMOTO T, NOBLE NA, MILLER DE, et al: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45:916-927, 1994
14. WATANABE T, YAMAMOTO T, IKEGAYA N, et al: Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephritis in rats. J Pathol 198:397-406, 2002
15. WOESSNER JB: The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophysics 93:440-447, 1961
16. AUSTIN HA, 3RD, MUENZ LR, JOYCE KM, et al: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382-391, 1983
17. LAN HY, MU W, NIKOLIC-PATERSON DJ, et al: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43:97-102, 1995
18. MORRISSEY JJ, KLAHR S: Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 52:926-933, 1997
19. DENNLER S, ITOH S, VIVIEN D, et al: Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. Embo J 17:3091-3100, 1998
20. MARTIN M, VOZENIN MC, GAULT N, et al: Coactivation of AP-1 activity and TGF-beta1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 15:981-989, 1997
21. CHEN SJ, YUAN W, LO S, et al: Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 183:381-392, 2000
22. STROSCHEIN SL, WANG W, LUO K: Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced smad-dependent transcriptional activation. J Biol Chem 274:9431-9441, 1999
23. MASSAGUE J, WOTTON D: Transcriptional control by the TGF-beta/Smad signaling system. Embo J 19:1745-1754, 2000
24. HELDIN CH, MIYAZONO K, TEN DUKE P: TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997
25. MIYAZONO K: Positive and negative regulation of TGF-beta signaling. J Cell Sci 113:1101-1109, 2000
26. CUTRONEO KR, PHAN SH: TGF-beta1-induced Smad 3 binding to the Smad 7 gene: Knockout of Smad 7 gene transcription by sense phosphorothioate oligos, autoregulation, and effect on TGF-beta1 secretion: bleomycin acts through TGF-beta1. J Cell Biochem 89:474-483, 2003
27. HOSOKAWA R, NONAKA K, MORIFUJI M, et al: TGF-beta 3 decreases type I collagen and scarring after labioplasty. J Dent Res 82:558-564, 2003
28. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
29. MORATH C, DECHOW C, LEHRKE I, et al: Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 12:2300-2309, 2001
30. OSTENDORF T, KUNTER U, VAN ROEYEN C, et al: The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 13:658-667, 2002
31. NAGARAJAN RP, ZHANG J, LI W, et al: Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 274:33412-33418, 1999
32. VON GERSDORFF G, SUSZTAK K, REZVANI F, et al: Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J Biol Chem 275:11320-11326, 2000
33. LABBE E, SILVESTRI C, HOODLESS PA, et al: Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 2:109-120, 1998